New anti-VEGF agents paired with upcoming drug delivery systems and monitoring technologies may lead to possible quarterly dosing regimens for patients with neovascular age-related macular degeneration.
Reducing the frequency of treatments and increasing the compliance of patients while maintaining good visual outcomes are the goals of wet AMD treatment.
“The biggest driver for long-term visual outcomes is continual dosing and continual treatment. Can we get to that point where we get to quarterly dosing? It’s an optimal way in the future to treat patients with the condition,”
Uncategorized